Navigation Links
Tourette Syndrome Association and Psyadon Pharmaceuticals to Collaborate on a Drug Trial for Tourette Syndrome Treatment
Date:5/11/2011

BAYSIDE, N.Y. and GERMANTOWN, Md., May 11, 2011 /PRNewswire-USNewswire/ -- The national Tourette Syndrome Association (TSA) and Psyadon Pharmaceuticals Inc. are pleased to announce their collaboration on a clinical trial to determine the potential efficacy of a novel drug, ecopipam, for managing the symptoms of the neurological disorder Tourette Syndrome (TS).

"This is the first time in our 39-year history that TSA has collaborated with the pharmaceutical industry and helped to fund a clinical drug trial for the potential treatment of TS. It marks the beginning of a new phase in our efforts to facilitate the development of effective and safe medications that are urgently needed for people with TS," said Judit Ungar, President of the NY-based not-for-profit organization.

The TSA will also assist with subject recruitment for the clinical trial of ecopipam, the rights to which are owned by Psyadon.

Marked by involuntary movements and sounds called "tics," TS is an inherited, neurobiological disorder frequently misunderstood by the public and often misdiagnosed medically.

Various off-label drugs are prescribed by medical professionals for TS, but of these, only two — pimozide and haloperidol — are approved by the FDA for the treatment of TS. These medications often provide only mild to moderate benefit and have poorly tolerated side effects that limit their use.

The FDA granted ecopipam an orphan-drug designation for the treatment of TS in September 2010. Richard Chipkin, President and CEO of Psyadon, stated, "We are honored to be selected as the first company the TSA has collaborated with on a clinical drug study. Experiments in animals suggest that ecopipam, which belongs to a class of agents referred to as dopamine D1 antagonists, interacts with nerve cells and systems in the brain that are thought to contribute to the development of tics and other symptoms in TS. Based on these studies, there is a good rationale and a logical basis for examining this drug's efficacy in reducing tic severity in individuals with TS."

The clinical trial, which has already begun, is a Phase 2a, open-label, non-randomized trial to examine the ability of ecopipam to both reduce tic severity and also to determine its safety in individuals (18 to 65 years of age) with TS. The study is being conducted at four sites across the U.S. by leading experts in the field of TS and is expected to last for several months. Further information on the clinical trial can be found at www.clinicaltrials.gov.

This study is designed, and will be conducted with safety being a top priority. It will be jointly monitored by TSA and Psyadon, and an independent Drug Safety Monitoring Board will be responsible for an impartial evaluation of the study.

"Neither ecopipam nor any other drug with a similar mechanism has been tested in TS. Therefore, the results of this study will be immensely valuable. The TSA-Psyadon collaboration sets the precedent for our future partnerships with the pharmaceutical industry," said Dr. Kevin McNaught, Vice President for TSA Medical and Scientific Programs.

Psyadon and TSA anticipate the data from this clinical trial will be released by mid-2012.

About TSA

Founded in 1972, TSA is a national voluntary organization with a three-pronged mission of education, research and service. TSA directs a network of over 33 chapters and more than 150 support groups across the country. For more information on TS, call 1-888-4-TOURET or visit http://tsa-usa.org.

About Psyadon Pharmaceuticals

Psyadon Pharmaceuticals, Inc. is a company that develops drugs for the treatment of diseases afflicting the central nervous system.  Founded in 2008, the firm is based in Germantown, Maryland. It receives financial support from New Enterprise Associates (Chevy Chase, MD) whose partner, Dr. James Barrett, acts as the Chairman of Psyadon's Board of Directors. For more information, visit www.psyadonrx.com.

Media Contacts:
TSA: Tracy Colletti-Flynn tracy.flynn@tsa-usa.org, 1-718-224-2999
Psyadon: Richard Chipkin  info@psyadonrx.com


'/>"/>
SOURCE Tourette Syndrome Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patients Living with Sjogrens Syndrome Encourage Communities to "Defy the Dry"
2. New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease
3. New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment
4. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
5. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
6. FDA Approves Horizant To Treat Restless Legs Syndrome
7. JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome
8. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
9. For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019
10. Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
11. VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today announced ... Raymond James and Associates, 38 th ... in Orlando, FL. Cowen and ... on March 7, 2017 in Boston, MA. ... 2017 in Miami, FL. ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The ... a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from ... 9.1% from 2016 to 2027. The market is estimated at $816m ... ... on to discover how you can exploit the future business opportunities ...
(Date:2/27/2017)... October – December 2016 Revenues amounted to SEK 0.3 ... Result after tax amounted to SEK -16.3 (-6.5) million, corresponding ... Cash flow from operating activities amounted to SEK -8.3 (-7.3) million ... Period full year 2016 ... amounted to SEK -39.5 (-29.5) million Result after tax amounted ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... ... February 26, 2017 , ... Today, ... the 7th Edition of International Social Design Awards. , The 7th A' ... System Designers, Governments and Institutions worldwide with realized projects and conceptual works. , ...
(Date:2/26/2017)... New York, New York (PRWEB) , ... February ... ... of luxury baby products for wholesale distribution in North America, today announced it ... established online sites. The company, which prides itself on crafting quality and unique ...
(Date:2/26/2017)... ... ... ODH, Inc.™ announced today it will exhibit and speak at the ... in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will present on ... health management. , ODH will also have an exhibit booth where attendees may speak ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
Breaking Medicine News(10 mins):